ICE Trial

  • Research type

    Research Study

  • Full title

    Individualised Cryoneurolysis to treat pain in the context of spasticity in the upper and lower Extremities: a pilot randomised controlled trial

  • IRAS ID

    1011743

  • Contact name

    Anton Pick

  • Contact email

    anton.pick@ouh.nhs.uk

  • Sponsor organisation

    Oxford University Hospitals NHS Foundation Trust

  • ISRCTN Number

    ISRCTN50433077

  • Research summary

    Spasticity is an umbrella term for impairments of muscle activity and control in people with damage to the brain and spinal cord. It is common and results in pain, stiffness, limb deformities, and contributes to difficulties in activities of daily living. Current treatment options, such as stretching, splinting, and Botulinum Toxin injections, are limited, and many people experience only partial reduction in spasticity and frequent repeated treatments are needed.
    Cryoneurolysis is a medical technique which involves the controlled freezing and thawing of nerves. It has been approved in the UK for the treatment of pain in the context of spasticity through the targeting of nerves which control problematic muscles. Oxford University Hospitals NHS Foundation Trust has been offering this treatment routinely since January 2024. This pilot study aims to improve our understanding of the potential effectiveness of this treatment and its potential side effects when compared with a more commonly used treatment (Botulinum Toxin).
    Participants will be randomly allocated to receive usual care with Botulinum Toxin (control group) or usual care with Cryoneurolysis (intervention group). We will assess pain, goal attainment, side effects, spasticity, disability and independence in daily activities, and movement of the arm and leg. Assessments will be at baseline and then 6-, 12-, 18-, and 24-weeks following treatment. Participants who are randomised to the control group will have the opportunity to receive cryoneurolysis treatment after the 12 week follow up assessment.
    The results of this study will inform the feasibility and guide future studies to examine the effectiveness of this treatment.

  • REC name

    Wales REC 1

  • REC reference

    25/WA/0286

  • Date of REC Opinion

    2 Dec 2025

  • REC opinion

    Further Information Favourable Opinion